This article summarized the latest R&D progress of Rilonacept, the Mechanism of Action for Rilonacept, and the drug target R&D trends for Rilonacept.

On September 6, 2023, Eli Lilly has registered a Phase III clinical trial (Study Code: ATTAIN-2) of the oral small molecule GLP-1R agonist Orforglipron (LY3502970) for the treatment of type 2 diabetes patients with obesity or overweight.

The 5-HT receptor, also known as the serotonin receptor, plays a crucial role in the human body.

Incyte Corp. founded in 2002 in Wilmington, Delaware, USA, is a global biopharmaceutical company dedicated to the discovery and development of new drugs.

On September 7, 2023, the new indication for the injectable drug Telitacicept developed by RemeGen was accepted by the Center for Drug Evaluation (CDE) for the treatment of rheumatoid arthritis (RA).

This article summarized the latest R&D progress of Idoxuridine, the Mechanism of Action for Idoxuridine, and the drug target R&D trends for Idoxuridine.

On September 6, 2023, Shanghai Yingli Pharmaceutical announced that its PI3Kδ inhibitor, Linperlisib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China for a new indication filing.

Adenosine receptors play a crucial role in various physiological processes within the human body.

ImmunoGen, Inc. is a biopharmaceutical company that was founded in 1981 and is based in Massachusetts, United States.

Genentech, a member of the Roche, announced that the U.S. FDA has accepted the company's BLA for the novel complement C5 monoclonal antibody Crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

This article summarized the latest R&D progress of Flurandrenolide, the Mechanism of Action for Flurandrenolide, and the drug target R&D trends for Flurandrenolide.

Korean biotech firm Alteogen Inc. has publicized the findings of their most recent Tergase® clinical study, wherein no occurrence of ADA (inclusive of neutralizing antibodies) was found.